10/08/2019 05:00:00

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Helius Medical Technologies, Inc. of Class Action Lawsuit and Upcoming Deadline - HSDT

NEW YORK, Aug. 10, 2019 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Helius Medical Technologies, Inc. (“Helius” or the “Company”) (NASDAQ:  HSDT) and certain of its officers.   The class action, filed in United States District Court, for the Southern District of New York, and indexed under 19-cv-07171, is on behalf of a class consisting of all persons and entities other than Defendants who purchased or otherwise Helius securities between November 9, 2017, and April 10, 2019, inclusive (the “Class Period”), seeking to pursue remedies under the Securities Exchange Act of 1934 (the “Exchange Act”).

If you are a shareholder who purchased Helius securities during the class period, you have until September 9, 2019, to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com.   To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

[Click here for information about joining the class action]

Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, or acquiring noninvasive technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator (“PoNS”), a medical device for the treatment of chronic balance deficit associated with a mild to moderate traumatic brain injury. Its PoNS device treats neurostimulation of cranial nerves via the tongue to restore lost function. 

The Complaint alleges that throughout the Class Period, the defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, the defendants failed to disclose to investors that: (i) the clinical study on the use of PoNS did not produce statistically significant results regarding the effectiveness of the treatment; (ii) as a result, the clinical study did not support the Company’s application for regulatory clearance; (iii) as a result, the Company was unlikely to receive regulatory approval of PoNS; and (iv) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis.

On January 25, 2019, the Company announced that it had received a request for additional data and information from the U.S. Food and Drug Administration (the “FDA”) related to the Company’s request for de novo classification and 510(k) clearance of PoNS.

On this news, the Company’s share price fell $0.48, or approximately 6%, to close at $7.13 per share on January 25, 2019, on unusually heavy trading volume.1

On April 10, 2019, the Company revealed that the FDA had denied regulatory clearance of the PoNS device because the Company had not provided sufficient clinical data to show the device was effective.

On this news, the Company’s share price fell $4.11, or more than 66%, to close at $2.10 per share on April 10, 2019, on unusually heavy trading volume.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT:

Robert S. Willoughby

Pomerantz LLP

rswilloughby@pomlaw.com

Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
17 Sep
CHEMM
Mullen jeg tror du hænger meget fast i hvordan markedet så ud for ½ år tilbage. Vi har i mellemtiden..
38
18 Sep
DANSKE
Her er lidt om de Berlingske løgnhistorier o Danske Bank - for det tilfælde I har lyst til at anlægg..
29
17 Sep
 
Kære EI,   Jeg har stor forståelse for at i skal tjene penge, for at kunne ove ville udbyde de ydels..
23
18 Sep
DANSKE
Hvor er dog dejligt at der er en journalist der går lidt dybere og ser hvad journalistik kan bruges ..
16
16 Sep
 
Jeg har skrevet til Nordnet at de bør beholde det gamle nordnet da jeg synes at det nye er noget bra..
16
19 Sep
DANSKE
ref 417838   Det er jo bare endnu en ubegavet journalist fra Berlingeren, der ikke ved en dyt om, Ja..
13
16 Sep
 
Det nye system er dybt uheldigt, både ifht. overblik - men også ifht. lay-out.    Nordnet kunne gøre..
13
20 Sep
VWS
Mon ikke lige vi skal spise brød til, inden vi konkluderer af GE løber med sejren. De har end ikke d..
12
16 Sep
VELO
Velkommen til ugens faste tråd om Veloxis & Envarsus 😊   Det har været endnu en stille uge for Velo..
12
18 Sep
DANSKE
INVESTOR1 : Jeg tror blot vi aktionærer i Danske Bank, er lidt mere vel afbalanceret som helhed. Vi ..
11

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
23 September 2019 00:55:52
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190829.2 - EUROWEB5 - 2019-09-23 01:55:52 - 2019-09-23 00:55:52 - 1000 - Website: OKAY